MX2011012409A - Metodos y composiciones de endoxifeno en el tratamiento de enfermedades mamiferas. - Google Patents

Metodos y composiciones de endoxifeno en el tratamiento de enfermedades mamiferas.

Info

Publication number
MX2011012409A
MX2011012409A MX2011012409A MX2011012409A MX2011012409A MX 2011012409 A MX2011012409 A MX 2011012409A MX 2011012409 A MX2011012409 A MX 2011012409A MX 2011012409 A MX2011012409 A MX 2011012409A MX 2011012409 A MX2011012409 A MX 2011012409A
Authority
MX
Mexico
Prior art keywords
endoxifen
compositions
treatment
methods
disorders
Prior art date
Application number
MX2011012409A
Other languages
English (en)
Spanish (es)
Inventor
Shoukath M Ali
Ateeq Ahmad
Moghis U Ahmad
Saifuddin Sheikh
Imran Ahmad
Original Assignee
Jina Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jina Pharmaceuticals Inc filed Critical Jina Pharmaceuticals Inc
Publication of MX2011012409A publication Critical patent/MX2011012409A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2011012409A 2009-05-21 2010-05-21 Metodos y composiciones de endoxifeno en el tratamiento de enfermedades mamiferas. MX2011012409A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/470,219 US20090291134A1 (en) 2006-11-21 2009-05-21 Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
PCT/US2010/035852 WO2010135703A2 (en) 2009-05-21 2010-05-21 Endoxifen methods and compositions in the treatment of mammalian diseases

Publications (1)

Publication Number Publication Date
MX2011012409A true MX2011012409A (es) 2012-03-14

Family

ID=43126804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012409A MX2011012409A (es) 2009-05-21 2010-05-21 Metodos y composiciones de endoxifeno en el tratamiento de enfermedades mamiferas.

Country Status (6)

Country Link
US (3) US20090291134A1 (cg-RX-API-DMAC7.html)
EP (1) EP2432462A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012527484A (cg-RX-API-DMAC7.html)
CA (1) CA2757838C (cg-RX-API-DMAC7.html)
MX (1) MX2011012409A (cg-RX-API-DMAC7.html)
WO (1) WO2010135703A2 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
DK2101731T3 (en) * 2006-11-21 2018-04-16 Jina Pharmaceuticals Inc ENDOXIFEN FOR USING CANCER TREATMENT
PL2685979T3 (pl) 2011-03-18 2017-02-28 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne do wstrzykiwania zawierające środek nierozpuszczalny w wodzie, środek przeciwpsychotyczny, laurynian sorbitanu i polisorbat 20
US12004868B2 (en) * 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10117881B2 (en) * 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
EP2714011B1 (en) 2011-06-03 2018-01-31 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
US10349884B2 (en) * 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
NZ630703A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising glycerol esters
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
EP2827868B8 (en) 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
EP2841566B1 (en) * 2012-04-24 2019-03-13 International Stem Cell Corporation Derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
CA2875330A1 (en) * 2012-06-05 2013-12-12 International Stem Cell Corporation Method of prevention of neurological diseases
WO2014002553A1 (ja) * 2012-06-29 2014-01-03 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
NZ631345A (en) 2012-09-19 2017-06-30 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
IN2013MU00646A (cg-RX-API-DMAC7.html) * 2013-03-04 2015-06-26 Intas Pharmaceuticals Ltd
KR101493877B1 (ko) * 2013-03-29 2015-02-16 농업회사법인 주식회사 생명의나무 스피나스테롤 당 유도체를 포함하는 골 질환 예방 또는 치료용 약학 조성물
EP3082768B1 (en) 2013-12-18 2023-02-22 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
JP6524110B2 (ja) 2014-03-20 2019-06-05 アルカームス ファーマ アイルランド リミテッド 注射速度が増大したアリピプラゾール調合物
CA2948823C (en) * 2014-05-12 2020-09-22 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen and metabolites thereof by mass spectrometry
WO2015187883A1 (en) 2014-06-03 2015-12-10 Signpath Pharma, Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
CN104892918B (zh) * 2015-05-29 2017-08-25 吕常海 磷脂酰乙醇胺‑羟基聚乙二醇衍生物及制备方法、脂质体造影剂和治疗肿瘤脂质体诊疗药物
WO2017189424A2 (en) 2016-04-27 2017-11-02 Signpath Pharma, Inc. Prevention of drug-induced atrio-ventricular block
TWI878810B (zh) * 2017-09-11 2025-04-01 美商阿托薩醫療公司 製造及使用因多昔芬(endoxifen)之方法
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CA3145867A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CN119390705A (zh) * 2019-10-09 2025-02-07 诺华股份有限公司 作为m4激动剂的5-氧杂-2-氮杂螺[3.4]辛烷衍生物
EP4132498A4 (en) 2020-04-10 2024-04-17 Jina Pharmaceuticals Inc. Endoxifen for the treatment of bipolar i disorder
WO2021205405A1 (en) * 2020-04-10 2021-10-14 Jina Pharmaceuticals, Inc. Endoxifen for the treatment of bipolar i disorder
CA3177260A1 (en) * 2020-04-10 2021-10-14 Jina Pharmaceuticals, Inc. Endoxifen for the treatment of bipolar i disorder
CA3190642A1 (en) * 2020-07-31 2022-02-03 Altaire Pharmaceuticals, Inc. Ophthalmic compositions for delivering meibum-like materials
US20240009259A1 (en) * 2020-11-20 2024-01-11 Academia Sinica Use of crassocephalum rabens extract in the prevention and/or treatment of fatigue and/or depression
WO2025137145A1 (en) * 2023-12-18 2025-06-26 Atossa Therapeutics, Inc. Oral formulations of (z)-endoxifen and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
JP2001507207A (ja) * 1996-05-01 2001-06-05 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 化合物を細胞に送達する方法
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
WO2005105063A1 (en) * 2004-05-03 2005-11-10 Universita' Degli Studi Di Firenze Pharmaceutical compositions containing serms for the treatment of alzheimer's disease
EP2076244B1 (en) * 2006-10-10 2016-12-07 Jina Pharmaceuticals Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
WO2008048194A1 (en) * 2006-10-20 2008-04-24 Yesilogluj Aysegul Yildiz Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder
CA2669355C (en) 2006-11-06 2012-10-30 Jina Pharmaceuticals, Inc. Guggulphospholipid methods and compositions
DK2101731T3 (en) * 2006-11-21 2018-04-16 Jina Pharmaceuticals Inc ENDOXIFEN FOR USING CANCER TREATMENT
US20120164075A1 (en) 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases

Also Published As

Publication number Publication date
EP2432462A2 (en) 2012-03-28
US20190231687A1 (en) 2019-08-01
US20210177752A1 (en) 2021-06-17
US11672758B2 (en) 2023-06-13
CA2757838A1 (en) 2010-11-25
JP2012527484A (ja) 2012-11-08
EP2432462A4 (en) 2013-11-13
CA2757838C (en) 2013-12-17
WO2010135703A3 (en) 2011-01-13
WO2010135703A2 (en) 2010-11-25
US20090291134A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
MX2011012409A (es) Metodos y composiciones de endoxifeno en el tratamiento de enfermedades mamiferas.
MX2020004099A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
MX2010002312A (es) Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
MY162903A (en) Methods of treatment of pancreatic cancer
PH12012500620A1 (en) Compounds
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
MX2012000565A (es) Derivados de triterpeno tipo lupeol como antivirales.
IN2012DN02081A (cg-RX-API-DMAC7.html)
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
TN2012000143A1 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
IN2012DN00971A (cg-RX-API-DMAC7.html)
IN2012DN03312A (cg-RX-API-DMAC7.html)
SG179120A1 (en) Novel compounds
MY150285A (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use
IN2012DN01435A (cg-RX-API-DMAC7.html)
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
MX2012006434A (es) Procesos para la preparacion de deferasirox, y polimorfos de deferasirox.
MY150931A (en) Substituted oxazolidinones and their use
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX342459B (es) 2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas sustituidas, como moduladores de kcnq2/3.
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2009151495A3 (en) Oxazole compounds, compositions and methods of use
MX2012006217A (es) Derivados de peroxido nuevos, su proceso de preparacion y su uso en medicina humana y en cosmeticos para el tratamiento o prevencion de acne.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal